Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
WADA Prohibition While GLP1 and cagrilintide individually have not been explicitly listed by WADA, several considerations apply: GLP-1 agonist precedent Other GLP-1 agonists are monitored for potential misuse in athletics Weight-class sports concern Rapid weight reduction capabilities raise concerns for sports with weight classifications Performance-enhancing potential Metabolic effects could theoretically affect athletic performance Monitoring program possible May be added to WADA monitoring program as use increases Athletes should consult with their sports governing bodies and anti-doping authorities before considering any GLP-1 or amylin analogue use
No, insurance is not required
The two compounds target entirely different systems and do not compete with one another
It includes everything in the Gold panel plus an iron panel, HbA1c (for blood sugar health), and Reverse T3
US$ 28.83
US$ 28.89
US$ 26.18
US$ 22.50
US$ 24.37
US$ 28.01
